139 related articles for article (PubMed ID: 31190005)
1. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.
Miller KC; Gertz MA; Buadi FK; Hayman SR; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Muchtar E; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2019 Dec; 54(12):2039-2050. PubMed ID: 31190005
[TBL] [Abstract][Full Text] [Related]
2. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
[TBL] [Abstract][Full Text] [Related]
3. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
[TBL] [Abstract][Full Text] [Related]
4. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
Vij R; Kumar S; Zhang MJ; Zhong X; Huang J; Dispenzieri A; Abidi MH; Bird JM; Freytes CO; Gale RP; Kindwall-Keller TL; Kyle RA; Landsburg DJ; Lazarus HM; Munker R; Roy V; Sharma M; Vogl DT; Wirk B; Hari PN
Biol Blood Marrow Transplant; 2015 Feb; 21(2):335-41. PubMed ID: 25445028
[TBL] [Abstract][Full Text] [Related]
6. Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
Parrish C; Rahemtulla A; Cavet J; Pearce RM; Kirkland K; Lee J; Cook M; Wilson K; Cook G;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1330-4. PubMed ID: 25843652
[TBL] [Abstract][Full Text] [Related]
7. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
8. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
12. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
13. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
16. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.
Gonsalves WI; Buadi FK; Ailawadhi S; Bergsagel PL; Chanan Khan AA; Dingli D; Dispenzieri A; Fonseca R; Hayman SR; Kapoor P; Kourelis TV; Lacy MQ; Larsen JT; Muchtar E; Reeder CB; Sher T; Stewart AK; Warsame R; Go RS; Kyle RA; Leung N; Lin Y; Lust JA; Russell SJ; Zeldenrust SR; Fonder AL; Hwa YL; Hobbs MA; Mayo AA; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA; Roy V
Bone Marrow Transplant; 2019 Mar; 54(3):353-367. PubMed ID: 29988062
[TBL] [Abstract][Full Text] [Related]
17. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.
Muta T; Miyamoto T; Kamimura T; Kanda Y; Nohgawa M; Ueda Y; Iwato K; Sasaki O; Mori T; Uchida N; Iida S; Fukuda T; Atsuta Y; Sunami K
Acta Haematol; 2018; 139(1):35-44. PubMed ID: 29339642
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
19. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
20. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
